Log In
BCIQ
Print this Print this
 

Vaxem-Hib (TAK-816)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionVaccine containing polyribosylribitol phosphate (PRP) with detoxified diphtheria toxin
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine
Latest Stage of DevelopmentMarketed
Standard IndicationHaemophilus
Indication DetailsPrevent Haemophilus Influenzae type b (Hib) infection
Regulatory Designation
PartnerTakeda Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$1.1M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/01/2009

Undisclosed

$1.1M

Undisclosed

Get a free BioCentury trial today